Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples-Reference-Cited by-同舟云学术

Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples

Published:2014 Issue:22 Volume:6 Page:9108-9115
ISSN:1759-9660
Container-title:Anal. Methods
language:en
Short-container-title:Anal. Methods

Author:

Odore Elodie¹²³⁴⁵,Lokiec François¹²³,Weill Sophie¹²³,Noel J. Kay⁶⁷,Herait Patrice⁶⁷,Bekradda Mohamed⁴⁵,Riveiro Maria Eugenia⁴⁵,Rezaï Keyvan¹²³

Affiliation:

1. RadioPharmacology Department

2. Curie Institute-René Huguenin Hospital

3. 92210 Saint-Cloud, France

4. Oncology Therapeutic Development

5. 92110 Clichy, France

6. Oncoethix SA

7. CH-1006 Lausanne, Switzerland

Abstract

Development and validation of a rapid and robust UPLC-MS/MS method for quantification of a novel bromodomain inhibitor, OTX015 and its application to a pharmacokinetic study.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Engineering,General Chemical Engineering,Analytical Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2014/AY/C4AY02249A

Reference21 articles.

1. Crystal Structure of the Human BRD2 Bromodomain

2. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis

3. The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation

4. Targeting MYC dependence in cancer by inhibiting BET bromodomains

5. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models;Leukemia & Lymphoma;2019-06-17

2. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors;Journal of Clinical Oncology;2018-10-20

3. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus;Oncotarget;2016-12-07

4. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma;Oncotarget;2016-08-01

5. OTX015 (MK-8628), a novel BET inhibitor, displaysin vitroandin vivoantitumor effects alone and in combination with conventional therapies in glioblastoma models;International Journal of Cancer;2016-07-30